Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): New Pharmacological Treatment Options for Crack-Cocaine Dependence in the Netherlands | Nuijten et al. BMC Psychiatry 2011 11 135 http www.biomedcentral.com 1471 -244X 11 135 BMC Psychiatry STUDY PROTOCOL Open Access Cocaine Addiction Treatments to improve Control and reduce Harm CATCH New Pharmacological Treatment Options for Crack-Cocaine Dependence in the Netherlands Mascha Nuijten1 Peter Blanken1 Wim van den Brink2 and Vincent Hendriks1 Abstract Background Cocaine particularly in its base form crack has become one of the drugs of most concern in the Netherlands being associated with a wide range of medical psychiatric and social problems for the individual and with significant public order consequences for society. Available treatment options for cocaine dependent users are limited and a substantial part of the cocaine dependent population is not reached by the addiction treatment system. Psychosocial interventions for cocaine dependence generally show modest results and there are no registered pharmacological treatments to date despite the wide range of medications tested for this type of dependence. The present study Cocaine Addiction Treatments to improve Control and reduce Harm CATCH investigates the possibilities and problems associated with new pharmacological treatments for crack dependent patients. Methods Design The CATCH-study consists of three separate randomised controlled open-label parallel-group feasibility trials conducted at three separate addiction treatment institutes in the Netherlands. Patients are either new referrals or patients already in treatment. A total of 216 eligible outpatients are randomised using prerandomisation double-consent design and receive either 12 weeks treatment with oral topiramate n 36 Brijder Addiction Treatment The Hague oral modafinil n 36 Arkin Amsterdam or oral dexamphetamine sustained-release n 36 Bouman GGZ Rotterdam as an add-on to cognitive behavioural therapy CBT or receive a 12week CBT only controls n 3 X 36 . Primary outcome in these feasibility trials is retention in the underlying .
